全文获取类型
收费全文 | 260篇 |
免费 | 12篇 |
专业分类
儿科学 | 5篇 |
基础医学 | 34篇 |
口腔科学 | 16篇 |
临床医学 | 13篇 |
内科学 | 92篇 |
皮肤病学 | 11篇 |
神经病学 | 24篇 |
特种医学 | 6篇 |
外科学 | 16篇 |
预防医学 | 5篇 |
眼科学 | 11篇 |
药学 | 27篇 |
肿瘤学 | 12篇 |
出版年
2022年 | 1篇 |
2021年 | 4篇 |
2020年 | 1篇 |
2019年 | 5篇 |
2018年 | 1篇 |
2017年 | 6篇 |
2015年 | 1篇 |
2014年 | 2篇 |
2013年 | 7篇 |
2012年 | 11篇 |
2011年 | 15篇 |
2010年 | 7篇 |
2009年 | 9篇 |
2008年 | 15篇 |
2007年 | 18篇 |
2006年 | 10篇 |
2005年 | 19篇 |
2004年 | 11篇 |
2003年 | 18篇 |
2002年 | 18篇 |
2001年 | 14篇 |
2000年 | 13篇 |
1999年 | 9篇 |
1998年 | 6篇 |
1997年 | 4篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 8篇 |
1991年 | 7篇 |
1990年 | 5篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1969年 | 2篇 |
1968年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有272条查询结果,搜索用时 343 毫秒
71.
Paolo Trisi Giorgio Perfetti Edoardo Baldoni Davide Berardi Marco Colagiovanni Giuseppe Scogna 《Clinical oral implants research》2009,20(5):467-471
Objectives: Measuring peak insertion torque in relation to different bone densities, the present study seeks to determine whether micromotion at the interface is related to primary stability achieved by increasing insertion torque.
Material and methods: A total of 120 Ti-Bone implants were placed in fresh bovine bone samples representing three density categories: hard, normal and soft (HNS). Five groups of peak insertion torque (20, 35, 45, 70 and 100 N/cm) were evaluated in the three bone density categories noted. Customized electronic equipment connected to a PC was used to register the peak and other insertion torque data. A loading device, consisting of a digital force gauge and a digital micrometer, was used to measure the micromovements of the implant during the application of 20, 25 and 30 N lateral forces. The data were analyzed for statistical significance by ANOVA and Spearman's rank correlation coefficient tests.
Results: A statistically significant difference between implant micromobility placed with different levels of torque and in different bone densities was demonstrated by ANOVA. Spearman's rank correlation coefficient showed a high dependency between the peak insertion torque and the observed micromovement. Particularly, in soft bone, it was not possible to achieve more than 35 N/cm of peak insertion torque.
Conclusions: Results showed that increasing the peak insertion torque reduces the level of implant micromotion. In addition, micromotion in soft bone was found to be consistently high, which could lead to the failure of osseointegration. Thus, immediate functional loading of implants in soft bone should be considered with caution. 相似文献
Material and methods: A total of 120 Ti-Bone implants were placed in fresh bovine bone samples representing three density categories: hard, normal and soft (HNS). Five groups of peak insertion torque (20, 35, 45, 70 and 100 N/cm) were evaluated in the three bone density categories noted. Customized electronic equipment connected to a PC was used to register the peak and other insertion torque data. A loading device, consisting of a digital force gauge and a digital micrometer, was used to measure the micromovements of the implant during the application of 20, 25 and 30 N lateral forces. The data were analyzed for statistical significance by ANOVA and Spearman's rank correlation coefficient tests.
Results: A statistically significant difference between implant micromobility placed with different levels of torque and in different bone densities was demonstrated by ANOVA. Spearman's rank correlation coefficient showed a high dependency between the peak insertion torque and the observed micromovement. Particularly, in soft bone, it was not possible to achieve more than 35 N/cm of peak insertion torque.
Conclusions: Results showed that increasing the peak insertion torque reduces the level of implant micromotion. In addition, micromotion in soft bone was found to be consistently high, which could lead to the failure of osseointegration. Thus, immediate functional loading of implants in soft bone should be considered with caution. 相似文献
72.
U Di Mario R Perfetti E Anastasi G Contreas L Crisà C Tiberti M A Amendolea C Masala 《Acta endocrinologica》1990,122(3):303-308
Insulin- and anti-immunoglobulin-antibodies have been recently reported in pre-diabetic subjects: the former has been proposed as a predictive marker of Type I diabetes in non-diabetic-subjects. To evaluate the diabetes-related specificity of these antibodies, the presence of insulin autoantibodies, using a recently developed and highly sensitive competitive radioimmune assay, and of anti-immunoglobulin antibodies together with that of immune complexes and of other autoantibodies has been investigated in patients with organ- or non-organ-specific autoimmune diseases. One hundred and eleven serum samples were assayed from patients with Graves' disease, primary hypothyroidism, chronic autoimmune thyroiditis, Addison's disease, chronic autoimmune hepatitis, pernicious anemia, lupus erythematosus, and rheumatoid arthritis, together with 45 serum samples from normal subjects. From patients with autoimmune diseases, 32.4% of all sera revealed values of insulin autoantibodies above the limit of positivity (p less than 0.001); anti-immunoglobulin antibodies were present in 4.1% of patients (NS); immune complexes were found in 19.5% (NS) of all patients, but in 38% of patients with Graves' disease and chronic hepatitis (p less than 0.02). There was a trend for multiple autoantibody positivity to be associated with high levels of insulin autoantibodies (p less than 0.05). Thus, whereas contrary to expectation anti-immunoglobulin antibodies are not associated with non-diabetes-related autoimmune diseases, increased humoral immunoresponsiveness to endogenous insulin appears to be related to autoimmunity in general rather than restricted to Type I diabetes. 相似文献
73.
Elisabetta Moscarella MD Alfonso Ielasi MD Alessandro Beneduce MD Giuseppe Ferrante MD PhD Andrea Carlo Pivato MD Mauro Chiarito MD Alberto Cappelletti MD Giulia Perfetti MD Valeria Magni MD Eugenio Prati MD Stefania Falcone MD Adele Pierri MD Stefano De Martini MD Matteo Montorfano MD Rosario Parisi MD David Rutigliano MD Nicola Locuratolo MD Angelo Anzuini MD Paolo Calabrò MD PhD Maurizio Tespili MD PhD Alberto Margonato MD PhD Alberto Benassi MD Carlo Briguori MD PhD Franco Fabbiocchi MD Bernhard Reimers MD Antonio Bartorelli MD PhD Antonio Colombo MD Cosmo Godino MD 《Catheterization and cardiovascular interventions》2019,94(7):972-979
74.
75.
Perfetti P Carlier P Strada P Gualandi F Occhini D Van Lint MT Ibatici A Lamparelli T Bruno B Raiola AM Dominietto A Di Grazia C Bregante S Zia S Ferrari GM Stura P Pogliani E Bacigalupo A 《Bone marrow transplantation》2008,42(9):609-617
Extracorporeal photopheresis (ECP) was given to 23 patients with steroid-refractory acute GVHD (aGVHD, grade II (n=10), III (n=7) or IV (n=6)). The median duration of ECP was 7 months (1-33) and the median number of ECP cycles in each patient was 10. Twelve patients (52%) had complete responses. Eleven patients (48%) survived and 12 died, 10 of GVHD with or without infections and two of leukaemia relapse. The average grade of GVHD was reduced from 2.8 (on the first day of ECP) to 1.4 (on day +90 from ECP) (P=0.08), and the average dose of i.v. methylprednisolone from 2.17 to 0.2 mg/kg/d (P=0.004). Complete responses were obtained in 70, 42 and 0% of patients, respectively, with grades II, III and IV aGVHD; complete responses in the skin, liver and gut were 66, 27 and 40%. Patients treated within 35 days from onset of aGVHD had higher responses (83 vs 47%; P=0.1). A trend for improved survival was seen in grade III-IV aGVHD treated with ECP as compared to matched controls (38 vs 16%; P 0.08). ECP is a treatment option for patients with steroid refractory aGVHD and should be considered early in the course of the disease. 相似文献
76.
The onset of type 2 diabetes is characterized by two determining factors: the insufficient ability to secrete insulin and/or the resistance to its biological action. Although in a very small proportion of individuals, one of those two metabolic abnormalities is the leading cause of diabetes, in most subjects, the coexistence of both appears to be necessary for the clinical manifestation of diabetes. Current biomedical research continues to clarify the relative contributions of these defects to the pathogenesis of type 2 diabetes, and novel pharmacological agents are specifically designed to correct either the impaired insulin secretory activity or the resistance to the action of insulin. The aim of this article is to provide a critical review of new sulfonylurea and non-sulfonylurea drugs that have been recently introduced for the treatment of diabetes, as well as drugs that are still under investigation and are likely to be made available in the near future. 相似文献
77.
Leone AM Galiuto L Garramone B Rutella S Giannico MB Brugaletta S Perfetti M Liuzzo G Porto I Burzotta F Niccoli G Biasucci LM Leone G Rebuzzi AG Crea F 《The American journal of cardiology》2007,100(3):397-403
Intracoronary injection of bone marrow stem cells seems to improve left ventricular (LV) function after acute myocardial infarction (AMI). Granulocyte colony-stimulating factor (G-CSF) could improve myocardial function and perfusion noninvasively through mobilization of stem cells into peripheral blood, although previous clinical trials have produced controversial results. Forty-one patients with large anterior wall AMI at high risk of unfavorable remodeling were randomized 1:2 to G-CSF (10 microg/kg/day for 5 days) or to conventional therapy. All patients underwent successful primary or rescue percutaneous coronary intervention. LV function was assessed by echocardiography before G-CSF administration, > or =5 days after AMI, and at follow-up. Only patients with a LV ejection fraction <50% at baseline were enrolled in the study. After a median follow-up of 5 months (range 4 to 6) patients treated with G-CSF exhibited improvement in LV ejection fraction, from 40 +/- 6% to 45 +/- 6% (p = 0.068) in the absence of LV dilation (LV end-diastolic volume from 147 +/- 33 to 144 +/- 46 ml at follow-up, p = 0.77). In contrast, patients treated conventionally exhibited significant LV dilation (LV end-diastolic volume from 141 +/- 35 to 168 +/- 41 ml, p = 0.002) in the absence of change in LV ejection fraction (from 38 +/- 6% to 38 +/- 8%, p = 0.95). However, when comparing patients treated with G-CSF with controls, variations in these parameters were significantly different at 2-way analysis of variance (p = 0.04 for LV end-diastolic volume, p = 0.02 for LV ejection fraction). In conclusion, G-CSF prevents unfavorable LV remodeling and improves LV function in patients with large anterior wall AMI and decreased LV ejection fraction after successful percutaneous coronary intervention. 相似文献
78.
Zaetta V Daniele L Perkovic D Pratticò F Barisa M Perfetti P Gabrieli A Buonocore F Winnicki M 《Blood pressure monitoring》2007,12(6):363-368
OBJECTIVE: To determine the accuracy of a new oscillometric home blood pressure (BP) monitor for arm BP measurement, the SAA-102, developed by the Sensacare Company. DESIGN: Evaluation of the SAA-102 was performed using validation protocols of the European Society of Hypertension (ESH), the Association for the Advancement of Medical Instrumentation (AAMI), and the British Hypertension Society (BHS). METHODS: The SAA-102 monitor was assessed on 33 participants according to ESH requirements, which are based on four zones of accuracy differing from the mercury standard by 5, 10, 15 mmHg or more. Then the oscillometric monitor was tested on 85 participants according to AAMI criteria which require a mean device-observers discrepancy within 5+/-8 mmHg. Finally, the electronic device was evaluated on 93 participants according to BHS requirements, which are based on five phases: before-use calibration, in-use assessment, after-use calibration, static device validation and report of the results. RESULTS: The SAA-102 passed all phases of the ESH international protocol for both systolic and diastolic blood pressure (SBP and DBP). The SAA-102 passed also AAMI criteria for SBP and DBP. The mean discrepancy between the SAA-102 and observers was 0.1+/-4.6 and -2.7+/-5.2 mmHg, for SBP and DBP, respectively. According to BHS protocol, the oscillometric monitor achieved final grading of A/A for SBP and DBP, respectively. CONCLUSION: These data show that the SAA-102 device satisfies ESH, AAMI, and BHS protocols for both SBP and DBP and may be recommended for everyday use for BP monitoring at home and in clinical practice. 相似文献
79.
Brooks NL Moore KS Clark RD Perfetti MT Trent CM Combs TP 《Diabetes, obesity & metabolism》2007,9(3):246-258
The metabolic syndrome is currently defined by various combinations of insulin resistance, obesity, dyslipidaemia and hypertension. The tendency for these risk factors to appear simultaneously suggests a single aetiologic basis. A low level of circulating adiponectin is associated with the appearance of each metabolic syndrome risk factor. The following review summarizes a large body of evidence that suggests a low level of circulating adiponectin represents an independent risk factor and a possible biomarker for the metabolic syndrome. An association between the metabolic syndrome and low adiponectin supports the view that the development of the metabolic syndrome may be triggered by a single underlying mechanism. Clinical studies in the future may show that a low level of circulating adiponectin is a primary biomarker for a specific cluster of metabolic syndrome risk factors rather than all the possible combinations of risk factors currently used to identify the metabolic syndrome. The significance of low circulating adiponectin in risk assessment models should ultimately be compared against insulin resistance, obesity, dyslipidaemia, hypertension and other metabolic syndrome risk factors presently under consideration. Adiponectin can be measured reliably in a clinical setting; circulating values of adiponectin do not fluctuate on a diurnal basis as much as insulin, glucose, triglycerides or cholesterol and only 2-4 microl of blood are currently needed for its measurement. 相似文献
80.
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor 总被引:2,自引:0,他引:2
Perfetti V Palladini G Brunetti L Sgarella A Brugnatelli S Gobbi PG Corazza GR 《European journal of gastroenterology & hepatology》2007,19(7):599-601
Bortezomib is the first anticancer proteasome inhibitor introduced into clinical practice. It has been recently approved for the treatment of multiple myeloma, an incurable plasma cell tumour that accounts for 10-15% of all haematologic malignancies and for approximately 20% of deaths. Gastrointestinal toxicity associated with the use of this drug is common but generally mild to moderate. Paralytic ileus in patients undergoing bortezomib treatment has been reported, although a definite attribution to bortezomib administration has not been established. We report a myeloma patient who developed severe paralytic ileus during bortezomib therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship. Awareness of the various potential gastrointestinal toxic effects of bortezomib is of relevance given the growing number of patients undergoing treatment with this important and effective new cancer drug. 相似文献